Astellas Pharma

From WikiMD's WELLNESSPEDIA

Astellas Pharma Inc. is a Japanese multinational pharmaceutical company, headquartered in Tokyo, Japan. The company was established on April 1, 2005, through the merger of Yamanouchi Pharmaceutical Co., Ltd. and Fujisawa Pharmaceutical Co., Ltd. Astellas is involved in the research, development, manufacture, import, and export of pharmaceuticals.

History[edit]

The history of Astellas Pharma Inc. is marked by the merger of two leading Japanese pharmaceutical companies, Yamanouchi Pharmaceutical Co., Ltd. and Fujisawa Pharmaceutical Co., Ltd. The merger was aimed at creating a more robust entity capable of competing on the global market.

Business Operations[edit]

Astellas Pharma Inc. operates in over 70 countries worldwide. The company's primary areas of focus include oncology, immunology, urology, and neuroscience. Astellas is also involved in the development of pharmaceuticals for infectious diseases and cardiovascular diseases.

Research and Development[edit]

Astellas Pharma Inc. has a strong commitment to research and development. The company's R&D efforts are focused on creating innovative drugs that can contribute to the health of patients around the world. Astellas has research facilities in Japan, North America, and Europe.

Products[edit]

Some of the key products of Astellas Pharma Inc. include Prograf, a drug used to prevent organ rejection in transplant patients, and Xtandi, a drug used to treat prostate cancer. The company also manufactures Vesicare, a drug used to treat overactive bladder.

Corporate Social Responsibility[edit]

Astellas Pharma Inc. is committed to fulfilling its corporate social responsibility through various initiatives. These include efforts to improve access to medicines, promote health education, and contribute to the sustainable development of society.

See Also[edit]

References[edit]


External Links[edit]

This article is a stub related to pharmacology. You can help WikiMD by expanding it!


  • 3D Structure of 2-arachidonoylglycerol
    3D Structure of 2-arachidonoylglycerol

Sponsored Health Resource

W8MD weight loss success

W8MD Weight Loss, Sleep & MedSpa

Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.

GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.

Book a W8MD appointment · View GLP-1 specials

Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.

Retrieved from "https://wikimd.org/index.php?title=Astellas_Pharma&oldid=6615597"